Information Provided By: 
Fly News Breaks for March 24, 2017
INSY
Mar 24, 2017 | 08:46 EDT
Janney Capital analyst Ken Trbovich said Insys Therapeutics' receipt of DEA scheduling of Syndros sets up a launch in the second half of the year, giving its sales reps a second product to promote and the company an opportunity to return to growth. Furthermore, the decision removes uncertainty about whether the company's ongoing DOJ investigation led to "stonewalling" of the company's regulatory efforts, noting that "while slow," both the DEA and FDA eventually took action. He keeps a Buy rating and $19 fair value estimate on Insys shares.
News For INSY From the Last 2 Days
There are no results for your query INSY
